| Literature DB >> 25169578 |
M P Verhagen1, N van Boven, J H Ruiter, G-J P Kimman, G J Tahapary, V A Umans.
Abstract
PURPOSE: Since several large trials have proven the effectiveness of implantable cardioverter-defibrillators (ICDs) in patients with left ventricular dysfunction, disadvantages have become more apparent. As the prognosis of patients with cardiovascular diseases is improving, assessment of ICD patients and re-evaluation of the current guidelines is mandatory. We aimed to evaluate differences in mortality and occurrence of (in)appropriate shocks in ICD patients with coronary artery disease (CAD) or dilated cardiomyopathy (DCM).Entities:
Year: 2014 PMID: 25169578 PMCID: PMC4188850 DOI: 10.1007/s12471-014-0595-z
Source DB: PubMed Journal: Neth Heart J ISSN: 1568-5888 Impact factor: 2.380
Baseline characteristics
| Characteristic | All ( | CAD ( | DCM ( | P Value |
|---|---|---|---|---|
| Age, years | 66 ± 10 | 67 ± 10 | 63 ± 11 | 0.047 |
| Male gender | 382(77) | 272(85) | 110(62) | <0.001 |
| LVEF, | 24 ± 7 | 25 ± 6 | 23 ± 8 | 0.13 |
| NYHA classification | ||||
| I–II | 359(80) | 233 (81) | 126(79) | 0.62 |
| III–IV | 87 (20) | 54(19) | 33(21) | |
| History of atrial fibrillation | ||||
| Permanent | 59(12) | 27(8) | 32(18) | 0.002 |
| Paroxysmal | 52(10) | 39(12) | 13(7) | 0.09 |
| QRS duration, ms | 132 ± 32 | 130 ± 31 | 136 ± 35 | 0.003 |
| QRS >120 ms | 254(53) | 159(52) | 95(57) | 0.29 |
| Serum creatinine (μmol/L) | 117 ± 79 | 123 ± 90 | 105 ± 51 | 0.06 |
| eGFR (ml/min/1.73 m2) | 65 ± 23 | 63 ± 23 | 68 ± 22 | 0.73 |
| Renal failure | 176(40) | 121(43) | 55(35) | 0.13 |
| Haemoglobin (mmol/L) | 8.6 ± 1.0 | 8.6 ± 1.0 | 8.6 ± 1.1 | 0.53 |
| Implanted device | ||||
| Atrial lead | 353(71) | 223(70) | 130(73) | 0.43 |
| CRT | 166(33) | 89(28) | 77(43) | <0.001 |
| Risk factors | ||||
| Diabetes | 95(19) | 69(22) | 26(15) | 0.06 |
| History of smoking | 213(50) | 144(53) | 69(45) | 0.12 |
| Hypertension | 147(42) | 136(44) | 75(44) | 0.90 |
| Cardiovascular medication | ||||
| Amiodarone | 56(11) | 42(13) | 14(8) | 0.08 |
| Beta-blocker | 457(93) | 294(93) | 163(93) | 0.95 |
| Digoxin | 29(6) | 12(4) | 17(10) | 0.008 |
| ACE inhibitor/ATII antagonist | 474(96) | 304(96) | 170(97) | 0.59 |
| Diuretics | 382(77) | 234(74) | 148(84) | 0.008 |
Continuous variables are expressed as mean±standard deviation. Categorical variables are expressed as count (percentage). Valid percentages may vary for some counts, because of missing values. ACE indicates angiotensin-converting enzyme; ATII angiotensin-II; eGFR estimated glomerular filtration rate; ICD Implantable cardioverter-defibrillator; LVEF Left ventricular ejection fraction; NYHA New York Heart Association
Fig. 1All-cause mortality, appropriate and inappropriate shocks in coronary artery disease (CAD) and dilated cardiomyopathy (DCM) patients
Fig. 2Kaplan-Meier survival curve of all-cause mortality. Coronary artery disease (CAD) versus dilated cardiomyopathy (DCM) patients
Fig. 3Kaplan-Meier hazard curve of a appropriate shocks and b inappropriate shocks. Coronary artery disease (CAD) versus dilated cardiomyopathy (DCM) patients